• 2022年度
• 2021年度
• 2020年度
• 2019年度
• 2018年度
• 2017年度
• 2016年度
• 2015年度
• 2014年度
• 2013年度

2020年度論文業績

• Sakaguchi M*, Yamaguchi H*, Nakajima N, Najima Y, Shono K, Marumo A, Omori I, Fujiwara Y, Terada K, Yui S, Wakita S, Mitaya M, Arai K, Kitano T, Doki N, Ohashi K, Inokuchi K. The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia. Leuk Res Rep.2020; 13: 100198. doi: 10.1016/j.lrr.2020.100198. eCollection 2020. * equal contribution.
• Omori I*, Yamaguchi H*, Hirakawa T, Inai K, Onai D, Marumo A, Yamanaka S, Sakaguchi M, Fujiwara Y, Wakita S, Okamoto M, Tamai H, Nakayama K, Yui S, Inokuchi K. Prognostic impact of hyperbilirubinemia in the early phase after allogeneic hematopoietic stem cell transplantation. J Nippon Med Sch. 2020; 87(3): 142-152. * equal contribution
• Yamaguchi H, Takezako N, Ohashi K, Oba K, Kumagai T, Kozai Y, Wakita H, Yamamoto K, Fujita A, Igarashi T, Yoshida C, Ohyashiki K, Okamoto S, Sakamoto J, Sakamaki H, Inokuchi K. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. Int J Hematol. 2020; 111(3): 401-408.
• Kurosawa S, Yamaguchi H, Yamaguchi T, Fukunaga K, Yui S, Kanamori H, Usuki K, Uoshima N, Yanada M, Takeuchi J, Mizuno I, Kanda J, Okamura H, Yano S, Tashiro H, Shindo T, Chiba S, Tomiyama J, Inokuchi K, Fukuda T. The prognostic impact of FLT3-ITD, NPM1 and CEBPa in patients with intermediate-risk acute myeloid leukemia after first relapse. Int J Hematol. 2020; 112(2): 200-209.
• Marumo A, Yamaguchi H, Hirakawa T, Inai K, Onai D, Omori I, Yamanaka S, Fujiwara Y, Sakaguchi M, Wakita S, Okamoto M, Yui S, Inokuchi K. Presence of promyelocytes in peripheral blood as a novel predictor of the optimal timing for single-step peripheral blood stem cell collection. J Nippon Med Sch. 2021;88(1):45-53.
• Terada K, Miyake K, Yamaguchi H, Miyake N, Yamanaka K, Kojima S, Ito E, Inokuchi K, OkadaT. TERT and TERC mutations detected in cryptic dyskeratosis congenita suppress telomerase activity. Int J Lab Hematol. 2020; 42(3): 316-321.
• Sakaguchi M, Nakayama K, Yamaguchi H, Mii A, Shimizu A, Inai K, Onai D, Marumo A, Omori I, Yamanaka S, Fujiwara Y, Fukunaga K, Ryotokuji T, Hirakawa T, Okabe M, Tamai H, Okamoto M, Wakita S, Yui S, Tsuruoka S, Inokuchi K. Risk factors for acute kidney injury and chronic kidney disease following allogeneic hematopoietic stem cell transplantation for hematopoietic malignancies. Acta Hematologica. Acta Haematol. 2020; 143(5): 452-464.
• Onishi Y, Mori T, Yamazaki H, Takenaka K, Yamaguchi H, Doki N, Uchida N, Ozawa Y, Ota S, Onizuka M, Ichinohe T, Atsuta Y. Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia. Ann Hematol. 2021;100(1):217-228.
• Kimura SI, Kanda Y, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K; Japan Febrile Neutropenia Study Group. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial. Int J Infect Dis. 2020 Nov;100:292-297.
• Nagai K, Shimoyama T, Yamaguchi H, Sakamoto Y, Suda S, Wakita S, Nishiyama Y, Inokuchi K, Kimura K. Clinical Characteristics and Brain MRI Findings in Myeloproliferative Neoplasms. J Neurol Sci. 2020 Sep 15;416:116990.
• Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S, Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S, Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I, Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M, Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K, Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H, Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y, Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M, Kamatani Y. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. Nat Genet. 2020; 52(7): 669-679.
• Kanda Y, Kimura SI, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K; Japan Febrile Neutropenia Study Group. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol. 2020; 38(8): 815-822.
• Kiyoi H, Yamaguchi H, Maeda Y, Yamauchi T. JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-1. Acute Myeloid Leukemia (AML). Int J Hematol. 2020; 111(5):595-613.
• 1. Ishibashi M, Takahashi R, Tsubota A, Sasaki M, Handa H, Imai Y, Tanaka N, Tsukune Y, Tanosaki S, Ito S, Asayama T, Sunakawa M, Kaito Y, Kuribayashi-Hamada Y, Onodera A, Moriya K, Komatsu N, Tanaka J, Odajima T, Sugimori H, Inokuchi K, Tamura H. SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. Mol Cancer Res. 2020; 18:632-643.
• Ishibashi M, Sunakawa-Kii M, Kaito Y, Kinoshita R, Asayama T, Kuribayashi Y, Inokuchi K, Morita R, Tamura H. The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma. Exp Hematol. 2020; 90:72-79.
• Tamura H, Ishibashi M, Sunakawa-Kii M, Inokuchi K. PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma. Cancers (Basel). 2020;12(4):924. doi: 10.3390/cancers12040924.
• Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; the Kanto CML, Shimousa Hematology Study Groups. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.Cancer Science. 2020; 111:2923-2934.